## Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 - Malta

# **SAFETY DATA SHEET**



FEIDOPUR ZD55 - All variants

### SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier Product name

: FEIDOPUR ZD55 - All variants

**1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use**: Paint.

#### 1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com responsible for this SDS

#### National contact

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

#### 1.4 Emergency telephone number

#### National advisory body/Poison Centre

 Telephone number
 : Malta Competition and Consumer Affairs Authority (MCCAA): +356 2395 2000

### **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Mam. Liq. 3, H226 Eye Irrit. 2, H319 Skin Sens. 1, H317 STOT SE 3, H336 Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

#### 2.2 Label elements

Hazard pictograms



Signal word	ning	
Hazard statements	<ul> <li>6 - Flammable liquid and vapour.</li> <li>7 - May cause an allergic skin reaction</li> <li>9 - Causes serious eye irritation.</li> </ul>	
	6 - May cause drowsiness or dizzines	
	2 - Harmful to aquatic life with long la	sting effects.
Precautionary statements		
Prevention	0 - Wear protective gloves. Wear eye 0 - Keep away from heat, hot surface rces. No smoking. 3 - Avoid release to the environment.	or face protection. s, sparks, open flames and other ignition

## **SECTION 2: Hazards identification**

SECTION 2. Hazarus	IC	ientification
Response	:	P304 + P312 - IF INHALED: Call a POISON CENTER or doctor if you feel unwell.
Storage	:	P403 + P233 - Store in a well-ventilated place. Keep container tightly closed.
Disposal	:	P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.
Hazardous ingredients	-	Contains: n-Butyl acetate; Acrylic polymer; Solvent naphtha (petroleum), light aromatic and Reaction mass of Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate
Supplemental label elements	:	Repeated exposure may cause skin dryness or cracking. Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	
2.3 Other hazards		
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do	:	None known.

not result in classification

## **SECTION 3: Composition/information on ingredients**

3.2 Mixtures	: Mixture	1			1
Product/ingredient name	Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Туре
ttanium dioxide	REACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7	≥25 - ≤50	Carc. 2, H351 (inhalation)	-	[1] [*]
n-Butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1	≥10 - ≤25	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	-	[1] [2]
Acrylic polymer	-	≤10	Eye Irrit. 2, H319 Skin Sens. 1B, H317	-	[1]
Solvent naphtha (petroleum), light aromatic	REACH #: 01-2119455851-35 EC: 265-199-0 CAS: 64742-95-6 Index: 649-356-00-4	≤10	Flam. Liq. 3, H226 STOT SE 3, H335 STOT SE 3, H336 Asp. Tox. 1, H304 Aquatic Chronic 2, H411 EUH066	-	[1]
2-Methoxy-1-methylethyl acetate	REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6 Index: 607-195-00-7	≤5	Flam. Liq. 3, H226 STOT SE 3, H336	-	[1] [2]
Xylene	REACH #: 01-2119488216-32 EC: 215-535-7	≤3	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332	ATE [Dermal] = 1100 mg/kg ATE [Inhalation	[1] [2]
Date of issue/Date of revision		e of previous is	sue : 21/03/2024	Version :4	2/24
EIDOPUR ZD55 - All variar	nts			Label No :1/20	)554

SECTION 3: Compo	sition/informat	ion on in	gredients		
	CAS: 1330-20-7 Index: 601-022-00-9		Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 (oral, inhalation) Asp. Tox. 1, H304	(vapours)] = 11 mg/ I	
2-butoxyethyl acetate	REACH #: 01-2119475112-47 EC: 203-933-3 CAS: 112-07-2	≤3	Acute Tox. 4, H302 Acute Tox. 4, H312 Acute Tox. 4, H332	ATE [Oral] = 500 mg/kg ATE [Dermal] = 1500 mg/kg ATE [Inhalation (vapours)] = 11 mg/ I	[1] [2]
Reaction mass of Bis (1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl- 4-piperidyl sebacate	REACH #: 01-2119491304-40 EC: 915-687-0 CAS: 1065336-91-5	≤0.62	Skin Sens. 1A, H317 Repr. 2, H361f Aquatic Acute 1, H400 Aquatic Chronic 1, H410	M [Acute] = 1 M [Chronic] = 1	[1]
propylidynetrimethanol	REACH #: 01-2119486799-10 EC: 201-074-9 CAS: 77-99-6	≤0.3	Repr. 2, H361fd	-	[1]
Fatty acids, tall-oil, compds. with oleylamine	REACH #: 01-2120101675-63	<0.1	Acute Tox. 4, H302 Skin Irrit. 2, H315 Skin Sens. 1A, H317 STOT RE 2, H373 (digestive system, immune system, liver) Aquatic Chronic 3, H412 See Section 16 for the full text of the H	ATE [Oral] = 500 mg/kg	[1]
			statements declared above.		

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section. <u>Type</u>

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[\*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter  $\leq$  10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

### **SECTION 4: First aid measures**

FEIDOPUR ZD55 - All variants

4.1 Description of first aid	neasures
Eye contact	: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
Inhalation	: Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Date of issue/Date of revision	: 27/05/2025 Date of previous issue : 21/03/2024 Version : 4 3/24

Label No :1/20554

### **SECTION 4: First aid measures**

Skin contact	: Wash skin thoroughly with soap and water or use recognised skin cleanser. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	: Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

#### 4.2 Most important symptoms and effects, both acute and delayed

#### **Over-exposure signs/symptoms** Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness **Skin contact** Adverse symptoms may include the following: 2 irritation redness dryness cracking Ingestion : No specific data.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	<ul> <li>Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.</li> </ul>
Specific treatments	: No specific treatment.

### **SECTION 5: Firefighting measures**

5.1 Extinguishing media	
Suitable extinguishing media	: Use dry chemical, $CO_2$ , water spray (fog) or foam.
Unsuitable extinguishing media	: Do not use water jet.

#### 5.2 Special hazards arising from the substance or mixture

Hazards from the	: Flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard.
substance or mixture	In a fire or if heated, a pressure increase will occur and the container may burst, with
	the risk of a subsequent explosion. This material is harmful to aquatic life with long
	lasting effects. Fire water contaminated with this material must be contained and
	prevented from being discharged to any waterway, sewer or drain.

SECTION 5: Firefighting measures		
Hazardous combustion products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide metal oxide/oxides	
5.3 Advice for firefighters		
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.	
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.	

### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful

to the environment if released in large quantities.

#### 6.3 Methods and material for containment and cleaning up

	······································
Small spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Absorb with an inert material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.
6.4 Reference to other sections	: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

### **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

### SECTION 7: Handling and storage

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

#### Seveso Directive - Reporting thresholds

#### Danger criteria

	Notification and MAPP threshold	Safety report threshold
₱5c	5000 tonnes	50000 tonnes

#### 7.3 Specific end use(s)

Recommendations

: Not available.

## Industrial sector specific solutions

: Not available.

### **SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

#### 8.1 Control parameters

#### **Occupational exposure limits**

Product/ingredient name	Exposure limit values		
<b>p</b> -Butyl acetate	EU OEL (Europe, 1/2022) STEL 15 minutes: 150 ppm. STEL 15 minutes: 723 mg/m <sup>3</sup> . TWA 8 hours: 241 mg/m <sup>3</sup> . TWA 8 hours: 50 ppm.		
2-Methoxy-1-methylethyl acetate	<b>EU OEL (Europe, 1/2022)</b> Absorbed through skin. TWA 8 hours: 50 ppm. TWA 8 hours: 275 mg/m <sup>3</sup> . STEL 15 minutes: 100 ppm. STEL 15 minutes: 550 mg/m <sup>3</sup> .		
Xylene	<b>EU OEL (Europe, 1/2022) [xylene, mixed isomers]</b> Absorbed through skin. TWA 8 hours: 50 ppm. TWA 8 hours: 221 mg/m <sup>3</sup> . STEL 15 minutes: 100 ppm.		
Date of issue/Date of revision : 27/05/2025	Date of previous issue: 21/03/2024Version: 46/24		
EIDOPUR ZD55 - All variants	Label No :1/20554		

2-butoxyethyl acetate		STEL 15 minutes: 442 mg/m <sup>3</sup> . <b>EU OEL (Europe, 1/2022)</b> Absorbed through skin. TWA 8 hours: 20 ppm. TWA 8 hours: 133 mg/m <sup>3</sup> . STEL 15 minutes: 50 ppm. STEL 15 minutes: 333 mg/m <sup>3</sup> .
Biological exposure indices		
Product/ingredien	t name	Exposure indices
No exposure indices known.		
Recommended monitoring procedures	European Stance assessment of e values and mea atmospheres - ( of exposure to c (Workplace atm for the measure	Id be made to monitoring standards, such as the following: lard EN 689 (Workplace atmospheres - Guidance for the exposure by inhalation to chemical agents for comparison with limit surement strategy) European Standard EN 14042 (Workplace Guide for the application and use of procedures for the assessment themical and biological agents) European Standard EN 482 ospheres - General requirements for the performance of procedure ment of chemical agents) Reference to national guidance nethods for the determination of hazardous substances will also be
Product/ingredient name		Result
Manium dioxide		<b>DNEL - General population - Long term - Inhalation</b> 28 µg/m³ <u>Effects</u> : Local
		<b>DNEL - Workers - Long term - Inhalation</b> 170 μg/m³ <u>Effects</u> : Local
n-Butyl acetate		<b>DNEL - General population - Long term - Oral</b> 2 mg/kg bw/day <u>Effects</u> : Systemic
		<b>DNEL - General population - Short term - Oral</b> 2 mg/kg bw/day <u>Effects</u> : Systemic
		<b>DNEL - General population - Long term - Dermal</b> 3.4 mg/kg bw/day <u>Effects</u> : Systemic
		<b>DNEL - General population - Short term - Dermal</b> 6 mg/kg bw/day <u>Effects</u> : Systemic
		<b>DNEL - Workers - Long term - Dermal</b> 7 mg/kg bw/day <u>Effects</u> : Systemic
		<b>DNEL - Workers - Short term - Dermal</b> 11 mg/kg bw/day <u>Effects</u> : Systemic
		<b>DNEL - General population - Long term - Inhalation</b> 12 mg/m <sup>3</sup> <u>Effects</u> : Systemic
		DNEL - General population - Long term - Inhalation 35.7 mg/m <sup>3</sup> Effects: Local
		DNEL - Workers - Long term - Inhalation

	501111015/	personal protection
		48 mg/m³ <u>Effects</u> : Systemic
		<b>DNEL - General population - Short term - Inhalation</b> 300 mg/m <sup>3</sup> <u>Effects</u> : Local
		<b>DNEL - General population - Short term - Inhalation</b> 300 mg/m <sup>3</sup> <u>Effects</u> : Systemic
		<b>DNEL - Workers - Long term - Inhalation</b> 300 mg/m³ <u>Effects</u> : Local
		<b>DNEL - Workers - Short term - Inhalation</b> 600 mg/m³ <u>Effects</u> : Local
		<b>DNEL - Workers - Short term - Inhalation</b> 600 mg/m <sup>3</sup> <u>Effects</u> : Systemic
Solvent naphtha (petroleum), lig	ht aromatic	<b>DNEL - General population - Long term - Inhalation</b> 0.41 mg/m <sup>3</sup> <u>Effects</u> : Systemic
		<b>DNEL - Workers - Long term - Inhalation</b> 1.9 mg/m³ <u>Effects</u> : Systemic
		<b>DNEL - General population - Long term - Inhalation</b> 178.57 mg/m³ <u>Effects</u> : Local
		<b>DNEL - General population - Short term - Inhalation</b> 640 mg/m³ <u>Effects</u> : Local
		<b>DNEL - Workers - Long term - Inhalation</b> 837.5 mg/m³ <u>Effects</u> : Local
		<b>DNEL - Workers - Short term - Inhalation</b> 1066.67 mg/m³ <u>Effects</u> : Local
		<b>DNEL - General population - Short term - Inhalation</b> 1152 mg/m <sup>3</sup> <u>Effects</u> : Systemic
		<b>DNEL - Workers - Short term - Inhalation</b> 1286.4 mg/m <sup>3</sup> <u>Effects</u> : Systemic
2-Methoxy-1-methylethyl acetate	9	<b>DNEL - General population - Long term - Inhalation</b> 33 mg/m <sup>3</sup> <u>Effects</u> : Local
		<b>DNEL - General population - Long term - Inhalation</b> 33 mg/m <sup>3</sup> <u>Effects</u> : Systemic
		<b>DNEL - General population - Long term - Oral</b> 36 mg/kg bw/day <u>Effects</u> : Systemic
Date of issue/Date of revision	: 27/05/2025	Date of previous issue : 21/03/2024 Version : 4

DNEL - Workers - Long term - Inhalation 275 mg/m<sup>3</sup> <u>Effects</u>: Systemic DNEL - General population - Long term - Dermal

**DNEL - General population - Long term - Dermal** 320 mg/kg bw/day <u>Effects</u>: Systemic

DNEL - Workers - Short term - Inhalation 550 mg/m<sup>3</sup> Effects: Local

**DNEL - Workers - Long term - Dermal** 796 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - General population - Long term - Oral** 5 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - General population - Long term - Inhalation** 65.3 mg/m<sup>3</sup> <u>Effects</u>: Local

**DNEL - General population - Long term - Inhalation** 65.3 mg/m<sup>3</sup> <u>Effects</u>: Systemic

**DNEL - General population - Long term - Dermal** 125 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - Workers - Long term - Dermal** 212 mg/kg bw/day <u>Effects</u>: Systemic

DNEL - Workers - Long term - Inhalation 221 mg/m<sup>3</sup> Effects: Local

**DNEL - Workers - Long term - Inhalation** 221 mg/m<sup>3</sup> <u>Effects</u>: Systemic

**DNEL - General population - Short term - Inhalation** 260 mg/m<sup>3</sup> Effects: Local

**DNEL - General population - Short term - Inhalation** 260 mg/m<sup>3</sup> <u>Effects</u>: Systemic

**DNEL - Workers - Short term - Inhalation** 442 mg/m<sup>3</sup> <u>Effects</u>: Local

DNEL - Workers - Short term - Inhalation 442 mg/m<sup>3</sup> Effects: Systemic

**DNEL - General population - Long term - Inhalation** 80 mg/m<sup>3</sup> <u>Effects</u>: Systemic

DNEL - Workers - Long term - Inhalation

: 21/03/2024

2-butoxyethyl acetate

**Xylene** 

Date of issue/Date of revision FEIDOPUR ZD55 - All variants Date of previous issue

: 27/05/2025

133 mg/m³ <u>Effects</u>: Systemic

DNEL - General population - Short term - Inhalation 200 mg/m<sup>3</sup> Effects: Local

**DNEL - General population - Long term - Oral** 8.6 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - General population - Short term - Oral** 36 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - General population - Short term - Dermal** 72 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - General population - Long term - Dermal** 102 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - Workers - Short term - Dermal** 120 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - Workers - Long term - Dermal** 169 mg/kg bw/day <u>Effects</u>: Systemic

DNEL - Workers - Short term - Inhalation 333 mg/m<sup>3</sup> Effects: Local

**DNEL - General population - Long term - Oral** 0.18 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - General population - Long term - Inhalation** 0.31 mg/m<sup>3</sup> <u>Effects</u>: Systemic

**DNEL - General population - Long term - Dermal** 0.9 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - Workers - Long term - Inhalation** 1.27 mg/m<sup>3</sup> Effects: Systemic

**DNEL - Workers - Long term - Dermal** 1.8 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - General population - Long term - Oral** 0.34 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - General population - Long term - Dermal** 0.34 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - General population - Long term - Inhalation** 0.58 mg/m<sup>3</sup> Effects: Systemic

Reaction mass of Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate

propylidynetrimethanol

Date of issue/Date of revision FEIDOPUR ZD55 - All variants : 27/05/2025 Date of previous issue

**DNEL - Workers - Long term - Dermal** 0.94 mg/kg bw/day <u>Effects</u>: Systemic

**DNEL - Workers - Long term - Inhalation** 3.3 mg/m<sup>3</sup> <u>Effects</u>: Systemic

#### **PNECs**

Not available.

8.2 Exposure controls	
Appropriate engineering controls	: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.
Individual protection meas	ures de la companya d
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection	: Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.
Skin protection	
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.
	Recommendations : Wear suitable gloves tested to EN374.
	< 1 hour (breakthrough time): Nitrile gloves. thickness > 0.3 mm
	1 - 4 hours (breakthrough time): 4H / Silver Shield® gloves.
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.
Other skin protection	<ul> <li>Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.</li> </ul>
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
	Filter type: A
	Filter type (spray application): A P

Date of issue/Date of revision	: 27/05/2025	Date of previous issue	: 21/03/2024	Version	:4 11/	/24
FEIDOPUR ZD55 - All variants				Label No :	120554	

Environmental exposure		
controls		

: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

### **SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### 9.1 Information on basic physical and chemical properties

Appearance	
Physical state	: Liquid.
Colour	: Various
Odour	: Slight
Odour threshold	: Not available.
Melting point/freezing point	: Not available.
Initial boiling point and boiling range	:

Ingredient name	°C	°F	Method
<mark>p</mark> ∠Butyl acetate	126	258.8	OECD 103
Solvent naphtha (petroleum), light aromatic	135 to 210	275 to 410	

Flammability	: Not available.
Lower and upper explosion limit	:
Flash point	: 🕅osed cup: 24°C (75.2°F)

ŝ

ż

#### Auto-ignition temperature

Ingredient name	°C	°F	Method
Solvent naphtha (petroleum), light aromatic	280 to 470	536 to 878	
2-Methoxy-1-methylethyl acetate	333	631.4	DIN 51794

Decomposition temperature	:	Not available.
рН	:	Not applicable.
Viscosity	:	Not available.
Solubility(ies)	:	
Not available.		
Solubility in water	:	Not available.
Partition coefficient: n-octanol/	:	Not applicable.

water

#### Vapour pressure

	Va	pour Press	ure at 20°C	Vapour pressure at 50°C			
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method	
p-Butyl acetate	11.25096	1.5	DIN EN 13016-2				
Xylene	6.7	0.89					
Relative density	: Not	available.					
Density	: 1.3	g/cm³					
Vapour density	: Not	available.					
Particle characteristics							
Median particle size	: Not	applicable.					

#### 9.2 Other information

#### 9.2.1 Information with regard to physical hazard classes



### **SECTION 9: Physical and chemical properties**

	Explosive properties	_
	Explosive properties	

: Not available.

**Oxidising properties** : Not available.

### 9.2.2 Other safety characteristics

Not applicable.

### **SECTION 10: Stability and reactivity**

10.1 Reactivity	:	No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	:	The product is stable.
10.3 Possibility of hazardous reactions	:	Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	:	Avoid all possible sources of ignition (spark or flame). Do not pressurise, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition.
10.5 Incompatible materials	:	Reactive or incompatible with the following materials: oxidising materials
10.6 Hazardous decomposition products	:	Under normal conditions of storage and use, hazardous decomposition products should not be produced.

### **SECTION 11: Toxicological information**

11.1 Information on hazard classes as defin	ed in Regulation (EC) No 1272/2008
Acute toxicity	
Product/ingredient name	<mark>Result</mark> Rat - Oral - LD50 10760 mg/kg EU
	<b>Rabbit - Dermal - LD50</b> 14112 mg/kg
	<b>Rat - Inhalation - LC50 Vapour</b> 0.74 mg/l [4 hours]
Solvent naphtha (petroleum), light aromatic	<b>Rat - Oral - LD50</b> 8400 mg/kg <u>Toxic effects</u> : Behavioral - Somnolence (general depressed activity) Behavioral - Tremor Lung, Thorax, or Respiration - Other changes
2-Methoxy-1-methylethyl acetate	<b>Rat - Oral - LD50</b> 8532 mg/kg
	<b>Rabbit - Dermal - LD50</b> >5 g/kg
Xylene	<b>Rat - Oral - LD50</b> 4300 mg/kg <u>Toxic effects</u> : Liver - Other changes Kidney, Ureter, and Bladder - Other changes
	<b>Rat - Inhalation - LC50 Vapour</b> 21.7 mg/l [4 hours]
2-butoxyethyl acetate	<b>Rat - Oral - LD50</b> 2400 mg/kg <u>Toxic effects</u> : Kidney, Ureter, and Bladder - Hematuria Kidney, Ureter, and Bladder - Other changes in urine composition
Date of issue/Date of revision : 27/05/2025	Date of previous issue     : 21/03/2024     Version     : 4     13/24

### SECTION 11: Toxicological information

Reaction mass of Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate

#### Rabbit - Dermal - LD50 1500 ma/ka

Toxic effects: Kidney, Ureter, and Bladder - Hematuria Kidney, Ureter, and Bladder - Other changes in urine composition Blood - Normocytic anemia

Rat - Oral - LD50 3230 mg/kg

### Rat - Dermal - LD50

>3170 mg/kg

propylidynetrimethanol

Rat - Oral - LD50

14000 mg/kg

#### **Conclusion/Summary [Product]** : Not available.

#### Acute toxicity estimates

Product/ingredient name	Oral (mg/ kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
FEIDOPUR ZD55	23255.8	25102.3	N/A	222.0	N/A
n-Butyl acetate	10760	14112	N/A	N/A	N/A
Solvent naphtha (petroleum), light aromatic	8400	N/A	N/A	N/A	N/A
2-Methoxy-1-methylethyl acetate	8532	N/A	N/A	N/A	N/A
Xylene	4300	1100	N/A	11	N/A
2-butoxyethyl acetate	500	1500	N/A	11	N/A
Reaction mass of Bis(1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate	3230	N/A	N/A	N/A	N/A
propylidynetrimethanol	14000	N/A	N/A	N/A	N/A
Fatty acids, tall-oil, compds. with oleylamine	500	N/A	N/A	N/A	N/A

#### Skin corrosion/irritation

#### **Product/ingredient name**

titanium dioxide n-Butyl acetate **Xylene** 2-butoxyethyl acetate

#### Result

Human - Skin - Mild irritant Duration of treatment/exposure: 72 hours Amount/concentration applied: 300 ug I

Rabbit - Skin - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 500 mg

#### Rat - Skin - Mild irritant

Duration of treatment/exposure: 8 hours Amount/concentration applied: 60 uL

Rabbit - Skin - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 500 mg

Rabbit - Skin - Moderate irritant Amount/concentration applied: 100 %

Rabbit - Skin - Mild irritant Amount/concentration applied: 500 mg

**Conclusion/Summary [Product]** : Not available.

: 27/05/2025 Date of previous issue · 21/03/2024

<b>SECTION 11: Toxicological informa</b>	ition
Serious eye damage/eye irritation	
Product/ingredient name P-Butyl acetate	Result Rabbit - Eyes - Moderate irritant Amount/concentration applied: 100 mg
Solvent naphtha (petroleum), light aromatic	Rabbit - Eyes - Mild irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 100 uL
Xylene	Rabbit - Eyes - Mild irritant Amount/concentration applied: 87 mg
	Rabbit - Eyes - Severe irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 5 mg
2-butoxyethyl acetate	Rabbit - Eyes - Mild irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 500 mg
Conclusion/Summary [Product] : Not availab	ble.
Respiratory corrosion/irritation Not available.	
Conclusion/Summary [Product] : Not availab	ble.
Respiratory or skin sensitization Not available.	
Skin Conclusion/Summary [Product] : Not availab	ble.
Respiratory Conclusion/Summary [Product] : Not availab	ble.
<u>Germ cell mutagenicity</u> Not available.	
Conclusion/Summary [Product] : Not availab	ble.
Carcinogenicity It has been observed that the carcinogenic hazard of leading to significant impairment of particle clearand Not available.	of this product arises when respirable dust is inhaled in quantitience mechanisms in the lung.
Conclusion/Summary [Product] : Mot availab	ble.
Reproductive toxicity Not available.	
Conclusion/Summary [Product] : Not availab	ble.
<u>Specific target organ toxicity (single exposure)</u> Product/ingredient name	Result
Date of issue/Date of revision: 27/05/2025Date of the contract of the contra	of previous issue         : 21/03/2024         Version         : 4         15/           Label No         : 1000000000000000000000000000000000000

SECTION 11: Toxicological information  Fund action  Fund								
Solveri naphtha (petroleum), light aromalic       STOT SE 3, H333 (Reco intervents)         2-Methoxy-1-methylethyl acetate       STOT SE 3, H333 (Narcotic effects)         Xytene       STOT SE 3, H333 (Narcotic effects)         Specific target organ toxicity (repeated exposure)       Result         Product/ingradient name       Rosult         Wiene       STOT SE 2, H373 (rat, inhalation)         Aspiration hazard       Result         Product/ingradient name       Result         Solvent naphtha (petroleum), light aromatic       ASPIRATION HAZARD - Category 1         Information on likely routes of exposure       Potential acute health effects         Eye contact       : @auses serious eye irritation.         Infamation       : Can cause central nervous system (CNS) depression. May cause drowsiness or draziness.         Skin contact       : @fating to the skin. May cause skin dryness and irritation. May cause an allergic skin reaction.         Symptoms related to the physical, chemical and toxicological characteristics         Eye contact       : Adverse symptoms may include the following: may or unconsciousness         Skin contact       : Mixerse symptoms may include the following: materia drawsiness/fatigue drawsiness/fat	SECTION 11: Toxicol	0	gical informati	on				
Xylene     STOT SE 3, H335 (Respiratory tract imitation)       Specific target organ toxicity (repeated exposure)     Product/Ingredient name       Product/Ingredient name     Result       Sylene     STOT RE 2, H373 (digestive system, immune system, liver)       Aspiration hazard     Product/Ingredient name       Product/Ingredient name     Result       Solvent naphtha (petroleum), light aromatic     ASPIRATION HAZARD - Category 1       Asylene     Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness       Skin contact     Extention       Symptoms related to the physical, chemical and toxicological characteristics       Eye contact     : Adverse symptoms may include the following: mause or vorniting headache       masse or vorniting headache     drowsiness/fatigue       Masses or vorniting headache     drowsiness/fatigue       Masses or vorniting headache     if drowsiness/fatigue       Masses or vorniting headache     drowsiness/fatigue       Masses or vorniting headache     drowsiness/fatigue       Masses or vorniting headache     drowsiness/fatigue       Inhal		lig	nt aromatic	STOT SE 3, H335 (Res	piratory tract i	rritation)		
Productingredient name         Result           Widene         STOT RE 2, H373 (oral, inhalation)           Fatty acids, tail-oil, compds. with oleylamine         STOT RE 2, H373 (digesible system, immune system, liver)           Aspiration hazard         Product/ingredient name         Result           Solvent naphtha (petroleum), light aromatic         ASPIRATION HAZARD - Category 1           Xylene         ASPIRATION HAZARD - Category 1           Not available.         Potential acute health effects           Eye contact         ::         Can cause central nervous system (CNS) depression. May cause an allergic skin reaction.           Information contact         ::         Solvent naghtha (betroleum), light aromatic and toxicological characteristics           Eye contact         ::         Can cause central nervous system (CNS) depression.           Sin contact         ::         Can cause central nervous system (SNS) depression.           Symptoms related to the physical, chemical and toxicological characteristics         Eye contact           Eye contact         ::         Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizoness/vertigo           Infamilion         ::         Adverse symptoms may include the following: imposite system (system)           Ingestion         ::         Merse symptoms may include the following: imposite system (system)           <		tate				rritation)		
Filty acids, tall-oil, compds. with oleylamine       STOT RE 2, H373 (oral, inhalation)         Stration hazard       Product/ingredient name       Result         Solvent naphtha (petroleum), light aromatic       ASPIRATION HAZARD - Category 1         Aylene       ASPIRATION HAZARD - Category 1         Aspression       ASPIRATION HAZARD - Category 1         Aylene       ASPIRATION HAZARD - Category 1         Aspression       ASPIRATION HAZARD - Category 1         Aspression       Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness.         Skin contact       Editating to the skin. May cause skin dryness and irritation. May cause an allergic skin reactor.         Ingestion       : Can cause central nervous system (CNS) depression.         Symptoms related to the physical, chemical and toxicological characteristics         Eye contact       : Adverse symptoms may include the following: nausea or writing neusea	Specific target organ toxicit	y (ı	<u>epeated exposure)</u>					
Faity acids, tall-oil, compds. with oleytamine       STOT RE 2, H373 (digestive system, immune system, liver)         Aspiration hazard       Product/ingredient name       Result         Solvent naphtifa (petroleum), light aromatic Xylene       ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1         Information on likely routes of exposure Not available.       Can cause central nervous system (CNS) depression. May cause drowsiness or dizzness.         Skin contact       :       Entiting to the skin. May cause skin dryness and irritation. May cause an allergic skin reaction.         Ingestion       :       Can cause central nervous system (CNS) depression.         Symptoms related to the physical, chemical and toxicological characteristics         Eye contact       :       Adverse symptoms may include the following: pain or imation watering redness         Inhalation       :       Adverse symptoms may include the following: inritiation reachess cracking         Ingestion       :       Not available.         Delayed and immediate effects as well as chronic effects from short and long-term exposure cracking       Not available.         Potential immediate effects       :       Not available.         Potential immediate       :       Not available.         Potential immediate       :       Not available.         Potential immediate       :	-			Result				
Productifugredient name       Result         Solvent naphtha (petroleum), light aromatic       ASPIRATION HAZARD - Category 1         Aspiration on likely routes of exposure       ASPIRATION HAZARD - Category 1         Not available.       Potential acute health effects         Eye contact       : Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness.         Skin contact       : Defatting to the skin. May cause skin dryness and iritation. May cause an allergic skin reaction.         Ingestion       : Can cause central nervous system (CNS) depression.         Symptoms related to the physical, chemical and toxicological characteristics         Eye contact       : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/serigue dizziness/vertigo unconsciousness         Skin contact       : Rotavailable.         Defating and immediate effects as well as chronic effects from short and long-term exposure         Short term exposure       Not available.         Potential immediate       : Not available.         effects       : Not available.         Potential delayed effects       : Not available.         effects       : Not available.         Detottial immediate       : Not available.         effects       : Not available.         Potential delayed effects       : Not available.         effects<		vith	oleylamine			immune syst	em, liv	er)
Solvent naphtha (petroleum), light aromatic       ASPIRATION HAZARD - Category 1         Xytene       ASPIRATION HAZARD - Category 1         Information on likely routes of exposure       Not available.         Potential acute health effects       Eye contact       : & Eauses serious eye irritation.         Inhalation       : Can cause central nervous system (CNS) depression. May cause drowsiness or dizzness.         Skin contact       : Ørfatting to the skin. May cause skin dryness and irritation. May cause an allergic skin reaction.         Ingestion       : Can cause central nervous system (CNS) depression.         Symptoms rolated to the physical, chemical and toxicological characteristics         Eye contact       : Adverse symptoms may include the following: pain or irritation watering redness         Inhalation       : Adverse symptoms may include the following: irritation redness         dizziness/vertigo       unconsciousness         Skin contact       : Roverse symptoms may include the following: irritation redness dryness cracking         Ingestion       : No specific data.         Delayed and immediate effects       : Not available.         effects       Potential delayed effects       : Not available.         Potential delayed offects       : Not available.         effects       Potential delayed offects       : Not available.         Potential inmediate       <	Aspiration hazard							
Xylene       ASPIRATION HAZARD - Category 1         Information on likely routes of exposure       Not available.         Potential acute health effects       Eve contact       : Eauses serious eye irritation.         Inhalation       : Can cause central nervous system (CNS) depression. May cause drowsiness or diziness.         Skin contact       : Ørfetting to the skin. May cause skin dryness and irritation. May cause an allergic skin reaction.         Ingestion       : Can cause central nervous system (CNS) depression.         Symptoms related to the physical, chemical and toxicological characteristics         Eye contact       : Adverse symptoms may include the following: pain or irritation watering redness         Inhalation       : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/faligue dizziness/vertigo unconsciousness         Skin contact       : Ørdverse symptoms may include the following: irritation redness dryness cracking         Ingestion       : No specific data.         Delayed and immediate effects as well as chronic effects from short and long-term exposure         Short term exposure       Potential immediate         Potential immediate       : Not available.         effects       :         Potential immediate       : Not available.         effects       :         Potential immediate       : Not available.         centat	-							
Not available.         Potential acute health offects         Eye contact       :         Can cause central nervous system (CNS) depression. May cause drowsiness or diziness.         Skin contact       :         Skin contact       :         Skin contact       :         Symptoms related to the physical, chemical and toxicological characteristics         Eye contact       :         Adverse symptoms may include the following: pain or irritation watering redness         Inhalation       :         Inhalation       :         Adverse symptoms may include the following: nausea or womiting headache dizones/vertigo unconsciousness         Skin contact       :         Reverse symptoms may include the following: irritation redness dryness.         Ingestion       :         Adverse symptoms may include the following: irritation redness dryness.         Ingestion       :         Mot available.         Delayed and immediate effects as well as chronic effects from short and long-term exposure         Potential immediate       :         Potential immediate       :         Potential immediate       :         Ingestion       :         Not available.         Conclusion/Summary (Product]       :         Po		lig	nt aromatic					
Potential acute health effects         Eye contact       :       Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness.         Skin contact       :       Defatting to the skin. May cause skin dryness and irritation. May cause an allergic skin reaction.         Ingestion       :       Can cause central nervous system (CNS) depression.         Symptoms related to the physical, chemical and toxicological characteristics         Eye contact       :       Adverse symptoms may include the following: pain or irritation watering redness         Inhalation       :       Adverse symptoms may include the following: nause or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness         Skin contact       :       Everse symptoms may include the following: irritation redness dryness cracking         Ingestion       :       Not seclific data.         Delayed and immediate effects as well as chronic effects from short and long-term exposure         Potential delayed effects       :         Potential immediate       :         Potential immediate       :         Ingestion       :         Potential immediate       :         Potential delayed effects       :         Potential immediate       :         Potential immediate       :         Potential immediate       :		of	<u>exposure</u>					
Eye contact       :       Eauses serious eye irritation.         Inhalation       :       Can cause central nervous system (CNS) depression. May cause drowsiness or diziness.         Skin contact       :       Defating to the skin. May cause skin dryness and irritation. May cause an allergic skin reaction.         Ingestion       :       Can cause central nervous system (CNS) depression.         Symptoms related to the physical, chemical and toxicological characteristics         Eye contact       :       Adverse symptoms may include the following: pain or irritation watering redness         Inhalation       :       Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue diziness/vertigo unconsciousness         Skin contact       :       Reverse symptoms may include the following: irritation redness         Ingestion       :       Adverse symptoms may include the following: irritation redness         Skin contact       :       Reverse symptoms may include the following: irritation redness         Skin contact       :       Reverse symptoms may include the following: irritation         redness       unconsciousness       Skin contact       :         Skin contact       :       Reverse symptoms may include the following: irritation         redness       unconsciousness       Skin contact       :         Short term exposure       Potentia								
Inhalation       : Can cause central nervous system (CNS) depression. May cause drowsiness or diziness.         Skin contact       : Defating to the skin. May cause skin dyness and irritation. May cause an allergic skin reaction.         Ingestion       : Can cause central nervous system (CNS) depression.         Symptoms related to the physical, chemical and toxicological characteristics         Eye contact       : Adverse symptoms may include the following: pain or irritation watering redness         Inhalation       : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness         Skin contact       : Mores symptoms may include the following: ritation redness dryness cracking         Ingestion       : Not variable.         Depayd and immediate effects as well as chronic effects from short and long-term exposure         Short term exposure       : Not available.         effects       : Not available.         effects       : Not available.         effects       : Not available.         Potential delayed effects       : Not available.         effects       : Not available.         Potential chronic health effects       : Not available.         effects       : Not available.         Potential chronic health effects       : Not available.         effects       : Not available.				1				
dizziness. Skin contact : Defatting to the skin. May cause skin dryness and irritation. May cause an allergic skin reaction. Ingestion : Can cause central nervous system (CNS) depression. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nause ar vormiting headache drowsiness/fatigue dizziness/vertigo unconsciousness Skin contact : Roverse symptoms may include the following: irritation redness Skin contact : Roverse symptoms may include the following: irritation redness cracking Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential diamediate offects : Not available. effects Potential delayed effects : Not available. Enclusion/Summary [Product] : Not available. Potential delayed effects : Not available. Potential chronic health effects Not available. Potential chronic health effects Not available. Conclusion/Summary [Product] : Not available. General : Potonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : No known significant effects or critical hazards. Date of issue/Date of revision : 2705/2025 Date of previous issue : 2103/2024 Versin : 4 1674								
skin reaction. Ingestion : Can cause central nervous system (CNS) depression. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain or irritation watering redness Inhalation : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness Skin contact : Rdverse symptoms may include the following: irritation redness Index extreme symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness Skin contact : Rdverse symptoms may include the following: irritation redness Ingestion : No specific data. Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential delayed effects : Not available. Long term exposure Potential delayed effects : Not available. Long term exposure Potential chronic health effects Rot available. Conclusion/Summary [Product] : Not available. Endition freetest Not available. General : Polonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. Carcinogenicity : Not known significant effects or critical hazards.			dizziness.			•		
Symptome related to the physical, chemical and toxicological characteristics         Eye contact       : Adverse symptoms may include the following: pain or irritation watering redness         Inhalation       :: Adverse symptoms may include the following: mausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness         Skin contact       :: Roverse symptoms may include the following: irritation redness dryness cracking         Ingestion       :: Not specific data.         Delayed and immediate effects as well as chonic effects from short and long-term exposure Short term exposure         Potential dialed effects       : Not available.         effects       : Potential delayed effects         Potential delayed effects       : Not available.         effects       : Potential chronic health effects         Rotavailable.       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27052025 Date of pr	Skin contact	1		n. May cause skin drynes	ss and irritation	n. May cause	e an all	ergic
Eye contact       : Adverse symptoms may include the following: pain or irritation watering redness         Inhalation       : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness         Skin contact       : Adverse symptoms may include the following: mausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness         Skin contact       : Adverse symptoms may include the following: intration redness dryness cracking         Ingestion       : No specific data.         Delayed and immediate effects as well as chronic effects from short and long-term exposure         Short term exposure         Potential immediate       : Not available.         effects       Potential delayed effects       : Not available.         Potential delayed effects       : Not available.         Potential chronic health effects       : Not available.         Potential chronic health effects       : Not available.         Potential chronic health effects       : Not available.         Conclusion/Summary [Product]       : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical	Ingestion	1	Can cause central r	nervous system (CNS) de	epression.			
pain or irritation watering redness         Inhalation       : Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness         Skin contact       : Adverse symptoms may include the following: irritation redness dryness cracking         Ingestion       : No specific data.         Delayed and immediate effects as well as chronic effects from short and long-term exposure         Short term exposure         Potential immediate       : Not available.         effects       : Not available.         Potential lelayed effects       : Not available.         effects       : Not available.         Potential delayed effects       : Not available.         effects       : Not available.         Potential delayed effects       : Not available.         Conclusion/Summary [Product]       : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dematitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carclinogenicity       : No known signif	Symptoms related to the ph	ysi	cal, chemical and to	oxicological characteris	<u>stics</u>			
nausea or vomiting         headache         drowsiness/fatigue         dizziness/vertigo         unconsciousness         Skin contact       : Kdverse symptoms may include the following:         irritation         redness         dryness         cracking         Ingestion       : No specific data.         Delayed and immediate effects as well as chronic effects from short and long-term exposure         Short term exposure         Potential immediate       : Not available.         effects         Potential delayed effects       : Not available.         effects         Potential delayed effects       : Not available.         effects       : Not available.         Potential chronic health effects       : Not available.         Potential chronic health effects       : Not available.         Potential chronic health effects       : Not available.         Conclusion/Summary [Product]       : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/bate of revisi	Eye contact	:	pain or irritation watering	may include the following	g:			
irritation       redness         dryness       cracking         Ingestion       : No specific data.         Delayed and immediate effects as well as chronic effects from short and long-term exposure         Short term exposure         Potential immediate       : Not available.         effects         Potential delayed effects       : Not available.         effects       : Not available.         effects       : Not available.         Potential delayed effects       : Not available.         effects       : Not available.         Potential chronic health effects       : Not available.         Potential chronic health effects       : Not available.         Conclusion/Summary [Product]       : Not available.         General       : Frolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025       Date of previous issue       : 21/03/2024       Versin : 4       16/24	Inhalation	:	nausea or vomiting headache drowsiness/fatigue dizziness/vertigo	may include the following	g:			
Delayed and immediate effects as well as chronic effects from short and long-term exposure         Short term exposure         Potential immediate       : Not available.         effects         Potential delayed effects       : Not available.         Long term exposure         Potential delayed effects       : Not available.         effects         Potential delayed effects       : Not available.         effects         Potential delayed effects       : Not available.         effects         Potential chronic health effects         Not available.         Conclusion/Summary [Product]       : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025       Date of previous issue       : 21/03/2024       Version :4       16/24	Skin contact	:	irritation redness dryness	may include the following	g:			
Short term exposure         Potential immediate       : Not available.         effects         Potential delayed effects       : Not available.         Long term exposure         Potential immediate       : Not available.         effects         Potential delayed effects       : Not available.         effects         Potential chronic health effects         Not available.         Potential chronic health effects         Not available.         Conclusion/Summary [Product]       : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025       Date of previous issue       : 21/03/2024       Version : 4       16/24	Ingestion	1	No specific data.					
Potential immediate       : Not available.         effects       Potential delayed effects       : Not available.         Long term exposure       Potential immediate       : Not available.         effects       Potential delayed effects       : Not available.         effects       Potential chronic health effects       : Not available.         Potential chronic health effects       : Not available.         Potential chronic health effects       : Not available.         Conclusion/Summary [Product]       : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025 Date of previous issue       : 21/03/2024       Version :4       16/24	Delayed and immediate effe	cts	as well as chronic	effects from short and	long-term ex	<u>posure</u>		
effects         Potential delayed effects       : Not available.         Long term exposure         Potential immediate       : Not available.         effects         Potential delayed effects       : Not available.         Potential chronic health effects         Not available.         Conclusion/Summary [Product]       : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Pate of issue/Date of revision       : 27/05/2025       Date of previous issue       : 21/03/2024       Version :4       16/24	<u>Short term exposure</u>							
Long term exposure         Potential immediate       : Not available.         effects         Potential delayed effects       : Not available.         Potential chronic health effects         Not available.         Conclusion/Summary [Product]       : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025       Date of previous issue       : 21/03/2024       Version : 4       16/24		1	Not available.					
Potential immediate       : Not available.         effects       Potential delayed effects       : Not available.         Potential chronic health effects       : Not available.         Not available.       Conclusion/Summary [Product]       : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025       Date of previous issue       : 21/03/2024       Version : 4       16/24		1	Not available.					
Potential delayed effects : Not available.         Potential chronic health effects         Not available.         Conclusion/Summary [Product] : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025 Date of previous issue : 21/03/2024 Version : 4 16/24	Potential immediate	:	Not available.					
Potential chronic health effects         Not available.         Conclusion/Summary [Product] : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025 Date of previous issue       : 21/03/2024 Version : 4 16/24		۰.	Not available					
Not available.         Conclusion/Summary [Product] : Not available.         General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025 Date of previous issue : 21/03/2024 Version : 4 16/24	_							
Conclusion/Summary [Product] : Not available.         General       : Frolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025 Date of previous issue : 21/03/2024 Version : 4 16/24			-					
General       : Prolonged or repeated contact can defat the skin and lead to irritation, cracking and/ or dermatitis. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.         Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025 Date of previous issue : 21/03/2024 Version : 4 16/24		odu	ct] : Not available					
Carcinogenicity       : No known significant effects or critical hazards.         Date of issue/Date of revision       : 27/05/2025       Date of previous issue       : 21/03/2024       Version       : 4       16/24			Prolonged or repeat or dermatitis. Once	ted contact can defat the sensitized, a severe alle				g and/
Date of issue/Date of revision       : 27/05/2025       Date of previous issue       : 21/03/2024       Version       : 4       16/24				•				
	Carcinogenicity	:	No known significar	nt effects or critical hazar	ds.			
			: 27/05/2025 Date of	previous issue : 21/0	3/2024			

### **SECTION 11: Toxicological information**

**Mutagenicity** 

- : No known significant effects or critical hazards.
- **Reproductive toxicity**
- : No known significant effects or critical hazards.

#### 11.2 Information on other hazards

#### **11.2.1 Endocrine disrupting properties**

Not available.

**Conclusion/Summary [Product]** : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

#### 11.2.2 Other information

Not available.

### **SECTION 12: Ecological information**

12.1 Toxicity	
Product/ingredient name	<b>Result</b> <b>Acute - LC50 - Marine water</b> Fish - Mummichog - <i>Fundulus heteroclitus</i> >1000000 μg/l [96 hours] <u>Effect</u> : Mortality
	Acute - LC50 - Fresh water Crustaceans - Water flea - <i>Ceriodaphnia dubia</i> - Neonate <u>Age</u> : <24 hours 3 mg/l [48 hours] <u>Effect</u> : Mortality
n-Butyl acetate	<b>Acute - LC50 - Fresh water</b> Fish - Fathead minnow - <i>Pimephales promelas</i> <u>Age</u> : 31 to 32 days; <u>Size</u> : 21.6 mm; <u>Weight</u> : 0.175 g 18000 μg/l [96 hours] <u>Effect</u> : Mortality
	<b>Acute - LC50 - Marine water</b> Crustaceans - Brine shrimp - <i>Artemia salina</i> 32 mg/l [48 hours] <u>Effect</u> : Mortality
Solvent naphtha (petroleum), light aromatic	<b>Acute - LC50</b> Fish 9.2 mg/l [96 hours]
	<b>Acute - EC50</b> Daphnia 3.2 mg/l [48 hours]
Reaction mass of Bis(1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl-4-piperidyl sebacate	<b>Acute - LC50</b> OECD [Fish, Acute Toxicity Test] Fish - <i>Brachydanio rerio</i> 0.9 mg/l [96 hours]
	<b>EC50</b> OECD [Alga, Growth Inhibition Test] Aquatic plants - <i>Desmodesmodus subspicatus</i> 1.68 mg/l [72 hours]
	<b>Chronic - NOEC</b> OECD [Daphnia Magna Reproduction Test] Daphnia - Daphnia 1 mg/l [21 days]
propylidynetrimethanol	<b>Acute - EC50 - Fresh water</b> Daphnia - Water flea - <i>Daphnia magna</i>

Date of issue/Date of revision FEIDOPUR ZD55 - All variants : 27/05/2025 Date of previous issue

<u>Age</u>: 1 to 3 days 13000000 µg/l [48 hours] <u>Effect</u>: Intoxication

#### Acute - LC50 - Marine water

Fish - Sheepshead minnow - *Cyprinodon variegatus* 14400000 µg/l [96 hours] <u>Effect</u>: Mortality

**Conclusion/Summary [Product]** : Not available.

#### 12.2 Persistence and degradability

Not available.

**Conclusion/Summary [Product]** : Not available.

#### **12.3 Bioaccumulative potential**

Product/ingredient name	LogPow	BCF	Potential
<b>R</b> -Butyl acetate Solvent naphtha (petroleum), light aromatic	2.3 -	- 10 to 2500	Low High
2-Methoxy-1-methylethyl acetate	1.2	-	Low
Xylene 2-butoxyethyl acetate	3.12 1.51	8.1 to 25.9	Low Low
2-butoxyethyl acetate propylidynetrimethanol	1.51 -0.47	- <1	Low Low

#### 12.4 Mobility in soil

#### Soil/water partition coefficient

Product/ingredient name	logKoc	Кос
<b>p</b> -Butyl acetate	1.52	33.2139
2-Methoxy-1-methylethyl acetate	0.36	2.31363
2-butoxyethyl acetate	2.05	112.842
propylidynetrimethanol	1.22	16.5101

#### Results of PMT and vPvM assessment

Product/ingredient name	PMT	Р	Μ	Т	vPvM	vP	vM
titanium dioxide	No	No	No	No	No	No	No
n-Butyl acetate	No	No	No	No	No	No	No
Acrylic polymer	No	No	No	No	No	No	No
Solvent naphtha (petroleum), light aromatic	No	No	No	No	No	No	No
2-Methoxy-1-methylethyl acetate	No	No	No	No	No	No	No
Xylene	No	No	No	No	No	No	No
2-butoxyethyl acetate	No	No	No	No	No	No	No
Reaction mass of Bis (1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl- 4-piperidyl sebacate	No	No	No	No	No	No	No
propylidynetrimethanol	No	No	No	No	No	No	No
Fatty acids, tall-oil, compds. with oleylamine	No	No	No	No	No	No	No

Mobility

: Not available.

: The product does not meet the criteria to be considered as a PMT or vPvM.

#### 12.5 Results of PBT and vPvB assessment

Date of issue/Date of revision FEIDOPUR ZD55 - All variants

**Conclusion/Summary** 

#### : 27/05/2025 Date of previous issue

### **SECTION 12: Ecological information**

### Regulation (EC) No. 1907/2006 [REACH]

Product/ingredient name	PBT	Р	В	Т	vPvB	vP	vB
titanium dioxide	No	No	No	No	No	No	No
n-Butyl acetate	No	No	No	No	No	No	No
Acrylic polymer	No	No	No	No	No	No	No
Solvent naphtha (petroleum), light aromatic	No	No	No	No	No	No	No
2-Methoxy-1-methylethyl acetate	No	No	No	No	No	No	No
Xylene	No	No	No	No	No	No	No
2-butoxyethyl acetate	No	No	No	No	No	No	No
Reaction mass of Bis (1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl- 4-piperidyl sebacate	No	No	No	No	No	No	No
propylidynetrimethanol	No	No	No	No	No	No	No
Fatty acids, tall-oil, compds. with oleylamine	No	No	No	No	No	No	No

### Regulation (EC) No. 1272/2008 [CLP]

Product/ingredient name	PBT	Р	В	т	vPvB	vP	vB
titanium dioxide	No	No	No	No	No	No	No
n-Butyl acetate	No	No	No	No	No	No	No
Acrylic polymer	No	No	No	No	No	No	No
Solvent naphtha (petroleum), light aromatic	No	No	No	No	No	No	No
2-Methoxy-1-methylethyl acetate	No	No	No	No	No	No	No
Xylene	No	No	No	No	No	No	No
2-butoxyethyl acetate	No	No	No	No	No	No	No
Reaction mass of Bis (1,2,2,6,6-pentamethyl- 4-piperidyl) sebacate and Methyl 1,2,2,6,6-pentamethyl- 4-piperidyl sebacate	No	No	No	No	No	No	No
propylidynetrimethanol	No	No	No	No	No	No	No
Fatty acids, tall-oil, compds. with oleylamine	No	No	No	No	No	No	No

Conclusion/Summary Regulation (EC) No. 1272/2008 [CLP]

12.6 Endocrine disrupting properties

Not available.

**Conclusion/Summary [Product]** 

: The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

: The product does not meet the criteria to be considered as a PBT or vPvB.

#### 12.7 Other adverse effects

No known significant effects or critical hazards.

: 27/05/2025 Date of previous issue

### **SECTION 13: Disposal considerations**

13.1 Waste treatment methods	
Product	
Methods of disposal :	The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
European waste : catalogue (EWC)	<b>Ø</b> 8 01 11*
Packaging	
Methods of disposal :	The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Special precautions :	This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

### **SECTION 14: Transport information**

	ADR/RID	ADN	IMDG	IATA
14.1 UN number or ID number	UN1263	UN1263	UN1263	UN1263
14.2 UN proper shipping name	PAINT	PAINT	PAINT	PAINT
14.3 Transport hazard class(es)	3	3	3	3
14.4 Packing group	111	111	111	
14.5 Environmental hazards	No.	Yes.	No.	No.

Additional information

**ADR/RID** 

**ADN** 

: <u>Tunnel code</u> (D/E)

: The product is only regulated as an environmentally hazardous substance when transported in tank vessels.

- IATA : The environmentally hazardous substance mark may appear if required by other transportation regulations.
- **14.6 Special precautions for : Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.
- **14.7 Maritime transport in** : Not relevant/applicable due to nature of the product.
- bulk according to IMO instruments

: 27/05/2025 Date of previous issue

### **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

#### Annex XIV - List of substances subject to authorisation

: Not listed

#### Annex XIV

None of the components are listed.

#### Substances of very high concern

None of the components are listed.

#### Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Product/ingredient name	%	Designation [Usage]
FEIDOPUR ZD55	≥90	3
Labelling :		

#### Labelling

Other EU regulations
Industrial emissions
(integrated pollution
prevention and control) -

Air		
Industrial emissions (integrated pollution prevention and control) - Water	:	Not listed
Explosive precursors	:	Not applicable.
Ozone depleting substance	es	(EU 2024/590)

Not listed.

### Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

#### Persistent Organic Pollutants Not listed.

### **Seveso Directive**

This product is controlled under the Seveso Directive.

### **Danger criteria**

Category	
₽5c	

#### International regulations

**Chemical Weapon Convention List Schedules I, II & III Chemicals** Not listed.

#### **Montreal Protocol**

Not listed.

#### **Stockholm Convention on Persistent Organic Pollutants**

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC) Not listed.

#### **UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

### **SECTION 15: Regulatory information**

15.2 Chemical safety assessment

: This product contains substances for which Chemical Safety Assessments are still required.

### **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

Abbreviations and acronyms	<ul> <li>ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RBN = REACH Registration Number</li> </ul>
	RRN = REACH Registration Number SGG = Segregation Group vPvB = Very Persistent and Very Bioaccumulative
	,

#### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
<b>F</b> am. Liq. 3, H226	On basis of test data
Eye Irrit. 2, H319	Calculation method
Skin Sens. 1, H317	Calculation method
STOT SE 3, H336	Calculation method
Aquatic Chronic 3, H412	Calculation method

#### Full text of abbreviated H statements

H226	Flammable liquid and vapour.
H302	Harmful if swallowed.
H304	May be fatal if swallowed and enters airways.
H312	Harmful in contact with skin.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H332	Harmful if inhaled.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.
H351	Suspected of causing cancer.
H361f	Suspected of damaging fertility.
H361fd	Suspected of damaging fertility. Suspected of damaging the unborn child.
H373	May cause damage to organs through prolonged or repeated exposure.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H411	Toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.
EUH066	Repeated exposure may cause skin dryness or cracking.

#### Full text of classifications [CLP/GHS]

Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Acute 1	SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1
Aquatic Chronic 2	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2
Aquatic Chronic 3	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3
Asp. Tox. 1	ASPIRATION HAZARD - Category 1
Carc. 2	CARCINOGENICITY - Category 2
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Flam. Liq. 3	FLAMMABLE LIQUIDS - Category 3
Repr. 2	REPRODUCTIVE TOXICITY - Category 2
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITISATION - Category 1
Skin Sens. 1A	SKIN SENSITISATION - Category 1A
Skin Sens. 1B	SKIN SENSITISATION - Category 1B
STOT RE 2	SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2
STOT SE 3	SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3

Date of issue/ Date of : 27/05/2025	
revision	
Date of previous issue : 21/03/2024	
Version : 4	

#### Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision FEIDOPUR ZD55 - All variants